{
    "ticker": "ORMP",
    "name": "Oramed Pharmaceuticals Inc.",
    "description": "Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of oral drug delivery systems. Founded in 2006 and headquartered in Jerusalem, Israel, Oramed is committed to transforming the treatment of diabetes through its innovative oral insulin capsule, which aims to improve patient compliance and outcomes. The company's flagship product, ORMD-0801, is designed to provide a non-invasive alternative to injectable insulin, with the goal of simplifying diabetes management for patients worldwide. Oramed's proprietary technology has the potential to revolutionize the treatment landscape for diabetes by enabling the delivery of biologics orally. The company is actively engaged in clinical trials and has received various regulatory approvals to advance its product candidates. In addition to diabetes, Oramed is exploring other therapeutic areas, including obesity and other metabolic disorders, through its innovative delivery technologies. With a strong pipeline and an experienced management team, Oramed is positioned to make significant advancements in the biopharmaceutical industry, aiming to enhance the quality of life for millions of patients suffering from chronic diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Jerusalem, Israel",
    "founded": "2006",
    "website": "https://www.oramed.com",
    "ceo": "Nathaniel A. (Nate) Greene",
    "social_media": {
        "twitter": "https://twitter.com/OramedPharma",
        "linkedin": "https://www.linkedin.com/company/oramed-pharmaceuticals/"
    },
    "investor_relations": "https://www.oramed.com/investor-relations",
    "key_executives": [
        {
            "name": "Nathaniel A. Greene",
            "position": "CEO"
        },
        {
            "name": "Miriam B. K. W. B. Wainstein",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diabetes Treatments",
            "products": [
                "ORMD-0801"
            ]
        }
    ],
    "seo": {
        "meta_title": "Oramed Pharmaceuticals Inc. | Oral Drug Delivery for Diabetes",
        "meta_description": "Oramed Pharmaceuticals Inc. focuses on developing oral insulin therapies to improve diabetes management. Learn about our innovative solutions and ongoing clinical trials.",
        "keywords": [
            "Oramed",
            "Oral Insulin",
            "Diabetes Treatment",
            "Biopharmaceuticals",
            "ORMD-0801"
        ]
    },
    "faq": [
        {
            "question": "What is Oramed known for?",
            "answer": "Oramed is known for its innovative oral insulin capsule designed to treat diabetes."
        },
        {
            "question": "Who is the CEO of Oramed?",
            "answer": "Nathaniel A. Greene is the CEO of Oramed Pharmaceuticals Inc."
        },
        {
            "question": "Where is Oramed headquartered?",
            "answer": "Oramed is headquartered in Jerusalem, Israel."
        },
        {
            "question": "What is Oramed's main product?",
            "answer": "Oramed's main product is ORMD-0801, an oral insulin capsule."
        },
        {
            "question": "When was Oramed founded?",
            "answer": "Oramed was founded in 2006."
        }
    ],
    "competitors": [
        "XLRN",
        "AMGN",
        "REGN",
        "NVO"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "SNY"
    ]
}